Irritable Bowel Syndrome Market
Sep 18, 2019
FDA approves Ibsrela to reduce the global burden of Irritable Bowel Syndrome
Recently the U.S. Food and Drug Administration has recommended the use of Ibsrela (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. A 50 mg, twice daily oral pill, Ibsrela is a small molecule that acts locally in the gastrointestinal tract to inhibit the sodium-hydrogen...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
